# Alvocade® (Bortezomib) Safety and Effectiveness Study

> **NCT06012383** · — · COMPLETED · sponsor: **NanoAlvand** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT06012383
- **Lead sponsor:** NanoAlvand
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06012383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06012383, "Alvocade® (Bortezomib) Safety and Effectiveness Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06012383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*